Norbert Avril

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi request reprint Functional PET imaging in cancer drug development
    Norbert Avril
    Department of Nuclear Medicine, Queen Mary, University of London, Barts and the London School of Medicine, London, EC1A 7BE, UK
    Future Oncol 3:215-28. 2007
  2. doi request reprint Gynecological cancers
    Norbert Avril
    Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary, University of London, London, UK
    Methods Mol Biol 727:171-89. 2011
  3. doi request reprint The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers
    Norbert Avril
    Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary University of London, London, UK
    Int J Urol 17:501-11. 2010
  4. ncbi request reprint 18F-FDG PET after radiofrequency ablation: Is timing everything?
    Norbert Avril
    Queen Mary University of London London, United Kingdom
    J Nucl Med 47:1235-7. 2006
  5. doi request reprint Response to therapy in breast cancer
    Norbert Avril
    Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary, University of London, London, United Kingdom
    J Nucl Med 50:55S-63S. 2009
  6. ncbi request reprint Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer
    Norbert Avril
    University of Pittsburgh Medical Center, Division of Nuclear Medicine, 200 Lothrop St, Pittsburgh, PA, 15213, USA
    J Clin Oncol 23:7445-53. 2005
  7. ncbi request reprint 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT
    Maren Bienert
    Department of Radiology, University of Pittsburgh Medical Center UPMC, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Eur J Nucl Med Mol Imaging 32:778-87. 2005
  8. ncbi request reprint Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers
    Regiane S Andrade
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Int J Radiat Oncol Biol Phys 65:1315-22. 2006
  9. ncbi request reprint Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy
    Samuel A Jacobs
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 11:7146s-7150s. 2005
  10. ncbi request reprint 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer
    Amer Shammas
    Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    J Nucl Med 48:221-6. 2007

Detail Information

Publications36

  1. ncbi request reprint Functional PET imaging in cancer drug development
    Norbert Avril
    Department of Nuclear Medicine, Queen Mary, University of London, Barts and the London School of Medicine, London, EC1A 7BE, UK
    Future Oncol 3:215-28. 2007
    ....
  2. doi request reprint Gynecological cancers
    Norbert Avril
    Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary, University of London, London, UK
    Methods Mol Biol 727:171-89. 2011
    ....
  3. doi request reprint The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers
    Norbert Avril
    Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary University of London, London, UK
    Int J Urol 17:501-11. 2010
    ..With disease progression and subsequent de-differentiation of prostate cancer, castrate resistant disease is more likely to present with lesions that have increased glucose metabolism...
  4. ncbi request reprint 18F-FDG PET after radiofrequency ablation: Is timing everything?
    Norbert Avril
    Queen Mary University of London London, United Kingdom
    J Nucl Med 47:1235-7. 2006
  5. doi request reprint Response to therapy in breast cancer
    Norbert Avril
    Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary, University of London, London, United Kingdom
    J Nucl Med 50:55S-63S. 2009
    ..Ultimately, the prediction of therapeutic effectiveness by PET and PET/CT could help to individualize treatment and to avoid ineffective chemotherapies, with their associated toxicities...
  6. ncbi request reprint Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer
    Norbert Avril
    University of Pittsburgh Medical Center, Division of Nuclear Medicine, 200 Lothrop St, Pittsburgh, PA, 15213, USA
    J Clin Oncol 23:7445-53. 2005
    ....
  7. ncbi request reprint 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT
    Maren Bienert
    Department of Radiology, University of Pittsburgh Medical Center UPMC, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Eur J Nucl Med Mol Imaging 32:778-87. 2005
    ..The aim of this study was to quantitatively assess changes in FDG uptake and tumour size following 90Y microsphere treatment (SIR-Spheres) using 18F-fluorodeoxyglucose (FDG) PET/CT imaging...
  8. ncbi request reprint Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers
    Regiane S Andrade
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Int J Radiat Oncol Biol Phys 65:1315-22. 2006
    ....
  9. ncbi request reprint Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy
    Samuel A Jacobs
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 11:7146s-7150s. 2005
    ..We treated eight patients with 90Y ibritumomab tiuxetan who had prior autologous stem cell transplant, but met all other treatment criteria...
  10. ncbi request reprint 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer
    Amer Shammas
    Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    J Nucl Med 48:221-6. 2007
    ..The aim of this study was to evaluate the use of coregistered PET and CT (PET/CT) in patients with suspected thyroid cancer recurrence...
  11. doi request reprint Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography
    Berna Degirmenci
    Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Nucl Med Commun 29:614-22. 2008
    ..We compared various semiquantitative approaches for the characterization of solitary pulmonary nodules (SPNs) using F-18 fluorodeoxyglucose PET/CT...
  12. ncbi request reprint Molecular positron emission tomography and PET/CT imaging in urological malignancies
    Tom Powles
    Department of Urology, Barts and the London School of Medicine, Queen Mary, University of London, London, UK
    Eur Urol 51:1511-20; discussion 1520-1. 2007
    ..The aim of this review is to provide an update on the current status of molecular PET and PET/CT imaging in urological malignancies...
  13. ncbi request reprint F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging
    Norbert Avril
    Department of Nuclear Medicine, Barts and the London School of Medicine, Queen Mary, University of London, West Smithfield QEII, London, EC1A 7BE, UK
    Radiol Clin North Am 45:645-57, vi. 2007
    ..Advances in technology, for example the development of dedicated breast imaging devices such as positron emission mammography, hold promise to improve the detection of primary tumors in the future...
  14. ncbi request reprint FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy
    Judith M Joyce
    Nuclear Medicine Division, Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Clin Nucl Med 30:564-8. 2005
    ..Simultaneous FDG PET and CT imaging (PET CT) provides coregistered functional PET images with anatomic CT images. We describe 2 cases of non-Hodgkin lymphoma treated in which response was followed using PET CT...
  15. doi request reprint Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation
    Tara Barwick
    Department of Radiology Nuclear Medicine, Imperial College Healthcare NHS Trust, London, UK
    Nucl Med Commun 30:908-17. 2009
    ..Further research should be facilitated by simplified synthesis of FLT with improved yields and an increasing commercial availability...
  16. doi request reprint Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT
    Tara Barwick
    Department of Nuclear Medicine, Barts and The London School of Medicine and NHS Trust, Queen Mary, University of London, West Smithfield QE II, London, UK
    Eur J Endocrinol 162:1131-9. 2010
    ....
  17. pmc New ways of assessing ovarian cancer response: metabolic imaging and beyond
    Andrea Rockall
    Department of Diagnostic Imaging, St Bartholomew s Hospital, West Smithfield, London, UK
    Cancer Imaging 12:310-4. 2012
    ..In this review article, we describe the current literature on functional imaging techniques in ovarian cancer response assessment, focusing on fluorodeoxyglucose-positron emission tomography...
  18. doi request reprint FDG-PET/CT as a molecular biomarker in ovarian cancer
    Ewa Nowosinska
    Department of Nuclear Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK
    Cancer Biomark 8:167-75. 2010
    ..The aim of this review is to demonstrate the value of FDG-PET-CT in diagnosis and management of patients with ovarian malignancies, outlining its advantages and limitations...
  19. ncbi request reprint Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer
    Melissa M Thrall
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Gynecol Oncol 105:17-22. 2007
    ..The aim of this study was to evaluate the use of co-registered PET/CT using F-18 fluorodeoxyglucose (FDG) for surveillance and follow-up of ovarian cancer patients to detect recurrent disease...
  20. doi request reprint Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer
    Irfan Kayani
    Department of Nuclear Medicine, University College Hospital, London, UK
    Clin Cancer Res 17:6021-8. 2011
    ..Three sequential scans were conducted to determine whether the timing of the investigation was relevant...
  21. ncbi request reprint Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report
    Dwight E Heron
    Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Int J Radiat Oncol Biol Phys 60:1419-24. 2004
    ..To prospectively study the impact on tumor and normal tissue delineation for RT planning by use of hybrid PET-CT simulation for patients with head-and-neck cancer...
  22. ncbi request reprint Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases
    Maren Bienert
    Department of Radiology, University of Pittsburgh Medical Center UPMC, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Eur J Nucl Med Mol Imaging 32:723. 2005
  23. doi request reprint Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring
    Iain Murray
    Department of Nuclear Medicine, Barts and the London School of Medicine, West Smithfield QE II, London, UK
    Eur J Nucl Med Mol Imaging 37:1643-53. 2010
    ..In this study we investigated to what extent a reduction in administered activity, synonymous with an overall reduction in repeated patient exposure, compromised the accuracy of quantitative measures using time-of-flight PET/CT...
  24. doi request reprint Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers
    Umasuthan Srirangalingam
    Department of Endocrinology, St Bartholomew s Hospital, West Smithfield, London, UK
    Clin Endocrinol (Oxf) 69:587-96. 2008
    ..The aim of this study was to describe the clinical manifestations of subjects with SDH-B gene mutations...
  25. doi request reprint Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours
    Umasuthan Srirangalingam
    Department of Endocrinology, St Bartholomew s Hospital, West Smithfield, London EC1A 7BE, UK
    Endocr Relat Cancer 16:515-25. 2009
    ..VHL-related tumours tend to be adrenal phaeochromocytomas, frequently bilateral and associated with a milder phenotype...
  26. ncbi request reprint GLUT1 expression in tissue and (18)F-FDG uptake
    Norbert Avril
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    J Nucl Med 45:930-2. 2004
  27. doi request reprint 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation
    Kunwar S S Bhatia
    Department of Academic Radiology, St Bartholomew s Hospital, London, UK
    Clin Endocrinol (Oxf) 69:181-8. 2008
    ..Evidence regarding the accuracy of [(123)I] metaiodobenzylguanidine (MIBG) imaging for phaeochromocytoma localization is currently limited to small series...
  28. pmc Interleukin-6 as a therapeutic target in human ovarian cancer
    Jermaine Coward
    Barts Cancer Institute, Queen Mary University of London, UK
    Clin Cancer Res 17:6083-96. 2011
    ..We investigated whether inhibition of interleukin 6 (IL-6) has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network...
  29. ncbi request reprint Single-detector helical CT in PET-CT: assessment of image quality
    Wolfgang Römer
    Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15213, USA
    AJR Am J Roentgenol 182:1571-7. 2004
    ..The aim of our study was to assess the impact of artifacts on the diagnostic quality of CT scans using a single-detector helical CT scanner in PET-CT imaging...
  30. doi request reprint Recommendations on the use of 18F-FDG PET in oncology
    James W Fletcher
    Department of Radiology, Indiana Purdue University, Indiana University School of Medicine, Indianapolis, Indiana 46202 5253, USA
    J Nucl Med 49:480-508. 2008
    ..Outcomes of interest included the use of (18)F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer...
  31. ncbi request reprint Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients
    Luis Gorospe
    Department of Radiology, La Paz University Hospital, Madrid, Spain
    Nucl Med Commun 26:671-87. 2005
    ....
  32. ncbi request reprint Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET
    Joerg Dose Schwarz
    Department of Gynecology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    J Nucl Med 46:1144-50. 2005
    ..The aim of this study was to evaluate the use of sequential 18F-FDG PET to predict response after the first and second cycles of standardized chemotherapy for metastatic breast cancer...
  33. ncbi request reprint Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience
    Maren Bienert
    Clinic for Nuclear Medicine, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, 10117, Berlin, Germany
    Eur J Nucl Med Mol Imaging 32:1225-33. 2005
    ..The aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative radioimmunotherapy using 131I-rituximab in previously heavily treated patients with B-cell non-Hodgkin's lymphoma (B-NHL)...
  34. ncbi request reprint Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer
    Stefanie Sassen
    Department of Pathology, Technische Universitat Munchen, Munich, Germany
    Hum Pathol 38:926-34. 2007
    ..The residual tumor size after neoadjuvant chemotherapy was the only criterion significantly correlated with treatment response and subsequent overall survival...
  35. ncbi request reprint Breast CT: a critical perspective
    Norbert Avril
    Future Oncol 2:325-7. 2006
  36. ncbi request reprint Intraoperative examination of sentinel lymph nodes by ultrarapid immunohistochemistry
    Jörg M Nährig
    Institute of Pathology, Technical University of Munich, Munich, Germany
    Breast J 9:277-81. 2003
    ..This technique may be a useful complementary tool for the intraoperative study of SLNs, particularly in tumors that are a diagnostic challenge, such as lobular carcinoma...